Discussion of the therapeutic effects of oncogene c-Src inhibitor on the triple negative breast cancer
ZHOU Shibo
YAO Yufeng
Abstract：Objective To explore adjuvant therapy on triple negative breast cancer (TNBC).Methods Develop triple negative breast cancer cell MDA-MB-231 cells,comparing with estrogen receptor (ER)and pro-gesterone receptor (PR)positive T47D cells,and HER2 positive Sk-Br-3 cells.They were treated with the in-hibitor of oncogene c-Src.MTT assay was used to measure cell growth.MTT and immunoelectrophoresis were performed to detect the growth of cells and the change of its signaling pathways.Results The c-Src inhibitor partially inhibited cell growth in T47D.It significantly abolished cell proliferation in triple negative MDA-MB-231 cells.However,it has no inhibitory effect on Sk-Br-3 cells.It was found that therapeutic effects of the c-Src inhibitor were related with the blocking cell growth signaling pathways in different cell lines.The HER2 in-hibitor significantly blocked S phase of cell cycles and cell growth in Sk-Br-3 cells,without any effect on MDA-MB-231 cells.Conclusions Inhibition of the tyrosine kinase activity of c-Src is an effective therapy to treat tri-ple negative breast cancer cells.
Keywords：triple negative breast canceroncogene c-Srcc-Src inhibitorgene therapy
Publication Date：2014-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 359-362 )